Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Histone deacetylases (HDACs) have been proved to be promising targets for the treatment of cancer, and five histone deacetylase inhibitors (HDACis) have been approved on the market for the treatment of different lymphomas. In our previous work, we designed a series of novel coumarin-containing hydro...

Full description

Bibliographic Details
Main Authors: Na Zhao, Feifei Yang, Lina Han, Yuhua Qu, Di Ge, Hua Zhang
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Molecules
Subjects:
coumarin
anti-tumor
hdac inhibitors
structural modification
anti-proliferative
Online Access:https://www.mdpi.com/1420-3049/25/3/717

Similar Items

Similar Items